News

Novozymes supplies Chinese pioneer
Enlarge image

BusinessSweden

Novozymes supplies Chinese pioneer

17.06.2012 - The Danish world market leader in enzyme technology, Novozymes A/S, will supply a large scale bioethanol production plant in China.

Baegsvaard – The deal was agreed during a visit from Hu Jintao, President of the People's Republic of China, in Copenhagen. Novozymes and its partner Shenqquan first announced the deal last month. China's Shengquan Group will start producing cellulosic ethanol in July, the company said.  According to Shenqquan, it will be the first in the world to do so on a commercial scale. The production will also be cost-competitive given that the feedstock, conventional ethanol, is a waste product from Shengquan's current production. The Chinese company is investing US $100m in the new groundbreaking facility. Novozymes will supply the enabling enzyme technology.

"When Shengquan opens its facility next month, it will be the first in the world," explains Steen Riisgaard, President and CEO of Novozymes. "It's fantastic to finally see this industry go commercial; for more than 10 years our researchers have worked to bring down the cost of producing ethanol from agricultural residues and household and industrial waste." Shengquan is a producer of furfural for resin production in the foundry industry. Furfural is produced from corncob xylose, with the cellulose from the corncob left behind as a waste product. Using Novozymes' enzymes, Shengquan will now be able to convert the cellulose into higher-value sugars that can be fermented to ethanol.  Shengquan will market the ethanol as an industrial solvent. "In order to continue to grow our country's economy at the same time as reducing our dependency on natural resources and minimizing the environmental impact, we need to start thinking of waste as an extremely valuable resource," comments Yi Lin Tang, President and Chairman of Shengquan Group. "Basically, we want and need to nurture a green and circular bioeconomy which is less dependent on fossil resources."

http://www.european-biotechnology-news.com/news/news/2012-02/novozymes-supplies-chinese-pioneer.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 25.04.2015